TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE B-

NCT04929236: Study to Evaluate Safety and Efficacy of Different PANZYGA Dose Regimens in Pediatric Chronic Inflammatory Demyelinating Polyradiculoneuropathy (CIDP) Patients

Sponsor: Octapharma · Phase: PHASE3 · Area: CNS_NEUROLOGY · Target Enrollment: 30 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$1,818,168

Rescue Site Savings

+$1,212,112

Unlock Full NCT04929236 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT04929236 Rescue Dossier →